Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
90Y-epratuzumab tetraxetan for Relapsed/Refractory B-ALL
NCT02844530Phase 2Withdrawn
- Sponsor
- CHU de Nantes
- Primary completion
- Jan 2017
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs)
- Countries
- 1
01
Overview
A Phase 2 trial of 90Y-epratuzumab tetraxetan in B cell acute lymphoblastic leukemia (B-ALL), sponsored by CHU de Nantes. Status: withdrawn.
02
Drugs
90Y-epratuzumab tetraxetan
03
Conditions
B cell acute lymphoblastic leukemia (B-ALL)
Beyond the preview
Go deeper on NCT02844530.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02844530.